CC-92328 for Multiple Myeloma

Phase-Based Progress Estimates
University of Alabama at Birmingham Hospital, Birmingham, ALMultiple MyelomaCC-92328 - Drug
All Sexes
What conditions do you have?

Study Summary

This trial is testing a new drug for people with multiple myeloma who have relapsed or are refractory to other treatments. The goal is to see if the drug is safe and tolerable and if it has any preliminary biological or clinical activity.

Eligible Conditions
  • Multiple Myeloma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

Study Objectives

3 Primary · 15 Secondary · Reporting Duration: Up to approximately 2 years

Week 9
Frequency of Anti-CC92328 antibodies (ADA)
Pharmacokinetics - AUC
Pharmacokinetics - Accumulation index of CC-92328
Pharmacokinetics - CL
Pharmacokinetics - Cmax
Pharmacokinetics - Cmin
Pharmacokinetics - Vd
Pharmacokinetics - t1/2
Pharmacokinetics - tmax
Presence of Anti-CC92328 antibodies (ADA)
Week 12
Incidence of Adverse Events (AEs)
Maximum Tolerated Dose (MTD)
Day 28
Dose-Limiting Toxicities (DLTs)
Year 2
Preliminary Efficacy - Duration of response
Preliminary Efficacy - Overall Response Rate (ORR)
Preliminary Efficacy - Overall Survival (OS)
Preliminary Efficacy - Progression-free Survival (PFS)
Preliminary Efficacy - Time to response

Trial Safety

Safety Progress

1 of 3

Similar Trials

Trial Design

1 Treatment Group

Administration of CC-92328
1 of 1

Experimental Treatment

70 Total Participants · 1 Treatment Group

Primary Treatment: CC-92328 · No Placebo Group · Phase 1

Administration of CC-92328
Experimental Group · 1 Intervention: CC-92328 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to approximately 2 years

Who is running the clinical trial?

CelgeneLead Sponsor
625 Previous Clinical Trials
123,049 Total Patients Enrolled
139 Trials studying Multiple Myeloma
39,250 Patients Enrolled for Multiple Myeloma
Marie Nguyen, MDStudy DirectorCelgene
3 Previous Clinical Trials
193 Total Patients Enrolled
Bristol-Myers SquibbStudy DirectorBristol-Myers Squibb
1,414 Previous Clinical Trials
3,310,512 Total Patients Enrolled
62 Trials studying Multiple Myeloma
21,766 Patients Enrolled for Multiple Myeloma

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

What are the objectives of this scientific experiment?

"The primary objective of this clinical trial, which will be monitored within a 12 week window after the final dose is administered, is to ascertain Maximum Tolerated Dose (MTD). Secondary endpoints being evaluated include Total body clearance of drug from serum (Pharmacokinetics - CL), Overall Survival (Time taken for death due to any cause post first CC-92328 dosage) and Area under Curve analysis." - Anonymous Online Contributor

Unverified Answer

Are there a range of medical centers conducting this investigation within city limits?

"This study is being conducted in numerous locations across the world, such as University Of Alabama At Birmingham Hospital in Birmingham, Local Institution - 203 in Halifax, and Local Institution - 205 in Montreal. Altogether 17 sites are participating." - Anonymous Online Contributor

Unverified Answer

How risk-free is CC-92328 for individuals?

"Due to the limited data supporting efficacy and safety, CC-92328 was assigned a score of 1 on our team's risk assessment scale." - Anonymous Online Contributor

Unverified Answer

What is the capacity for participants in this investigation?

"To conclude this clinical trial, the sponsor Celgene needs to recruit 70 qualified participants from multiple sites such as University Of Alabama At Birmingham Hospital in Birmingham and Local Institution - 203 in Halifax." - Anonymous Online Contributor

Unverified Answer

Are there still openings available for this clinical experiment?

"Correct. The details hosted on demonstrate that this research, which was initially posted on October 5th 2021, is still in need of participants. Seventy individuals are needed to be recruited from 17 physical trial centres." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.